Table 2 Methods to enhance the anti-fibrosis effect of MSC-EVs in different organs
From: Mesenchymal stem cell-derived extracellular vesicles in therapy against fibrotic diseases
| Â | Exogenous modification | Bio-gel | Preconditioning |
|---|---|---|---|
Liver | miR-122 [55] | PEG hydrogels [58] | IFN-γ [59] |
| Â | miR-181-5p [56] | Â | Â |
| Â | mmu_circ_0000623 [57] | Â | Â |
| Â | miR-145-5p [7] | Â | Â |
Kidney | KMP2 [61] | RGD hydrogels [63] | Oct-4 overexpression [65] |
| Â | GDNF [62] | Collagen matrix [64] | |
Heart | miR-146a [71] | PGN hydrogels [68] | FNDC5 or irisin [73] |
|  | IMTP [72] | Alginate hydrogels [69] | HIF-1α [74] |
| Â | Â | (RADA)4-SDKP hydrogels [70] | B2M-deficient [75] |
| Â | Â | Â | Ischemia [76] |
| Â | Â | Â | Hypoxia [77] |
Skin | TSG-6 [78] | BSSPD hydrogels [79] | Â |
Tendon adhesion | Â | Â | Hydroxycamptothecin [80] |
Urethra |  |  | TNFα [81] |